ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Sex and age disparities in goserelin safety: a global pharmacovigilance study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of goserelin combined with laparoscopic surgery for endometriosis and its effects on ovarian function and oxidative stress.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Goserelin, a synthetic analogue of gonadotropin-releasing hormone, is widely used in breast cancer and prostate cancer. However, significant sex-based disparities exist in its therapeutic effects and safety profiles. What's more, current evidence remains insufficient to characterize age-related adverse drug event (ADEs) risks. Given these gaps, comprehensive real-world studies are required to systematically analyze ADEs in male and female patients separately. The analytical dataset was derived from the FAERS (2004 Q1-2025 Q1) and VigiBase (1987.01.01-2025.07.01) databases. Disproportionality analysis was performed using the reporting odds ratio and information component. All statistical analyses and visualizations were conducted using Microsoft Excel 2019, R4.4.2, and GraphPad Prism. The FAERS database recorded 8,245 ADEs (2,325 female; 3,190 male), while VigiBase contained 10,524 (3,274 female; 4,941 male). Baseline clinical outcomes revealed higher mortality rates and more serious reports in males. System organ class analysis demonstrated that males showed greater susceptibility to general disorders and administration site conditions. Several strong signals in the preferred term level not currently listed in the drug label were identified, including neutropenia, jaundice, and pleural effusion. Age-stratified analysis indicated ADEs predominantly occurred in males aged 65-74 years and females aged 40-54 years. The most frequently reported events, hot flush and interstitial lung disease, displayed stronger associations in male patients. Using real-world pharmacovigilance data, we identify sex- and age-related safety disparities for goserelin, supporting individualized monitoring and risk management to enhance treatment safety.
Indexed as
Identifiers
41796237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.